Where opportunity meets readiness.

Japan is a vast but comparatively underserved oncology market.

Japan represents the second largest pharmaceutical market in the world with $60 billion USD in annual sales and a high prevalence of age-related diseases, with the incidence of cancer growing at the highest rate. However, in terms of cancer therapies, Japan is a surprisingly underserved market, lagging the West in terms of new drug approvals and a cancer fatality rate that is higher than in the United States and Europe. Japanese health authorities have recognized this “drug lag” as a national priority and are committed to eliminating it.

Atani is a cleverly designed pharmaceutical conduit for emerging innovations.

There is a wealth of novel cancer products from Western pharmaceutical and biotechnology companies from which cancer patients in Japan could benefit. Atani, with its first-hand knowledge of the Japanese market, strong, international management team, and local networks, is partnering with innovative European and U.S. biotechnology and pharmaceutical companies to expedite the process of bringing their most successful oncology products to market in Japan where they are sorely needed.